2024年4月24日，浙江大学医学院附属第一医院/良渚实验室黄河/胡永仙/王东睿/张鸿声等团队在国际顶尖医学期刊《新英格兰医学杂志》（NEJM）发表了题为：Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis的临床研究论文。该研究在10例复发或难治性CD7阳性白血病或淋巴瘤患者中测试了一种...
1. Hu Y, Zhang M, Yang T, et al. Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis. New Engl J Med. Published online April 24, 2024. doi:10.1056/NEJMoa2313812 2. CD7 CAR-T bridging t...
2024年4月25日,顶级学术期刊The New England Journal of Medicine发表浙江大学医学院附属第一医院黄河/胡永仙团队最新研究成果“Sequential CD7 CAR-T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis”[1]。研究首次提出CD7 CAR-T与异基因造血干细胞移植序贯治疗这一新颖的治疗策略。来自浙江大学医学院附属...
多项临床研究评估了异基因HSCT作为CAR-T细胞治疗后的巩固治疗,以维持长期肿瘤消除并降低复发风险。然而,这种“过渡”方法包括了HSCT前的预处理化疗和GVHD预防药物,这些药物可清除残留的CAR-T细胞,并有发生重度毒性作用的风险,从而可能使患者...
pre-HSCT myeloablation and graft-versus-host disease (GVHD) prophylaxis agents have toxic effects and could eradicate residual CAR T cells and compromise antitumor effects. Whether the integration of CAR T-cell therapy and allogeneic HSCT can preserve CAR T-cell function and improve tumor control ...
近日,浙江大学医学院附属第一医院/良渚实验室黄河/胡永仙/王东睿/张鸿声等团队在国际顶尖医学期刊《新英格兰医学杂志》(NEJM)发表了题为:Sequential CD7 CAR-T Therapy and Allo-HSCT without GvHD-prophylaxis Drugs的临床研究论文。该研究首次提出CD7 CAR-T与异基因造血干细胞移植序贯治疗的一体化策略,无需传统的清...
研究者对这两个队列的患者在CAR-T细胞输注至allo-HSCT期间的感染情况进行了详细分析，包括病因学和影像学诊断。在感染发生方面，张弦教授指出，CD19 CAR-T队列与CD7 CAR-T队列的总体感染发生率无显著差异，分别为3%（n=22）和7%（n=17）（P=33）。此外，研究者还对细菌、病毒和真菌感染进行了亚群分析。结果...
CD7 CAR T-cell therapy offered an opportunity to reduce tumor burden and bridge to allo-HSCT. Treatment-related toxicity was moderate but manageable. To our knowledge, this is the first case of r/r AML successfully treated with CD7 CAR T-cell therapy. The result suggests that CD7 CAR T-...
Chimeric antigen receptor (CAR)-T cell therapy against T cell malignancies faces major challenges including fratricide between CAR-T cells and product contamination from the blasts. Allogeneic CAR-T cells, generated from healthy donor T cells, can provid
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) The main purpose of this study is to evaluate the Composite Complete Remission Rate (CRc) of WU-CART-007 in...